GEN Exclusives

More »

GEN News Highlights

More »
Jul 13, 2012

Janssen Taps Genmab for Bispecific Antibody Platform

  • Janssen Biotech is making a $3.5 million up-front payment to Genmab to access the latter’s DuoBody platform for the development of bispecific antibodies against multiple target combinations. The deal follows just six weeks after Genmab inked a DuoBody partnership with Novartis.

    Under terms of the latest collaboration with Janssen, the latter will fully fund all Genmab’s research on up to 10 DuoBody programs. The firm could earn up to another $175 million in potential milestone and license payments for each product, plus future sales royalties.

    “Since the introduction of our DuoBody platform in 2010, we have believed in its potential to become the preferred technology for next-generation bispecific antibody therapeutics,” comments CEO Jan van de Winkel, Ph.D. “Today’s announcement is another indicator that the pharmaceutical industry recognizes our leadership in the therapeutic antibody field.”


Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

New Drugs for Ebola

Do you think that biopharma companies should not have to go through the normal drug approval process in order to get potential life-saving therapies to Ebola patients more quickly?